Hemoglobin therapy in hemodialysis

Details Hemoglobin therapy in hemodialysis Hemoglobin therapy in hemodialysis

A - Human Necessities

61

K

A61K 38/42 (2006.01)

Patent

CA 2180529

Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.

De faibles doses d'hémoglobine réticulée par diaspirine et ne contenant pas de stroma sont administrées aux patients suivant un traitement par hémodialyse, de manière à obtenir une stabilisation au niveau sanguin et à éviter les phases d'hypotension chez les sujets à risques. Lorsqu'elle est pratiquée de manière prophylactique pendant l'hémodialyse, la thérapie par hémoglobine contribue également à limiter le recours à des interventions ultérieures visant à réguler l'instabilité de l'appareil circulatoire.

Affiliated with

Also associated with

Rating

Hemoglobin therapy in hemodialysis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hemoglobin therapy in hemodialysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemoglobin therapy in hemodialysis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1444662